参考文献 References
[1] 殷爱军,孔北华. 免疫检查点抑制剂在子宫内膜癌治疗中的研究进展[J]. 现代妇产科进展,2022,31(1):75-79.
[2] World Health Organization． Cancer Today[EB/OL]．[2021- 1-18]． https: / /gco． iarc． fr/today /online-analysis-table
[3] Siegel ＲL, Miller KD. Jemal A. Cancer statistics，2016[J]． CA Cancer J Clin，2016，66( 1) : 7-30.
[4] 中华医学会妇科肿瘤学分会,孔北华,刘继红,谢幸,马丁.妇科肿瘤免疫检查点抑制剂临床应用指南[J].现代妇产科进展,2021,30(10):737-756.
[5] 宗丽菊,向阳. 难治性子宫内膜癌免疫治疗研究进展[J]. 实用妇产科杂志,2020,36(6):415-417.
[6] 谢玲玲,林荣春,林仲秋.《2022 NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志,2021,37(12):1227-1233.
[7] 徐锋,张真发. 肿瘤源性外泌体调节肺癌免疫微环境及作为肺癌生物标志物的应用[J]. 癌症,2021, 40(9): 388-393.
[8] 王佳森,张妍,付晓雪,等. 宫颈癌免疫学发病机制研究进展[J]. 国际妇产科学杂志,2022,49(2):207-211.
[9] Echizen K, Oshima H, Nakayama M, Oshima M. The inflammatory microenvironment that promotes gastrointestinal cancer development and invasion. Adv Biol Regul. 2018 May;68:39-45.
[10] Mittal S, Brown NJ, Holen I. The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn. 2018 Mar;18(3):227-243.
[11] Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001 Jan; 27(1):68-73.
[12] 李鹏飞,贺拥军,林玮,文泽馨,张燕丽,张敏.Foxp3+调节性T细胞在肿瘤微环境中的研究进展[J].西藏医药,2020,41(5):150-153.
[13] Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target [J]. Cancer Sci, 2019, 110(7): 2080-2089.
[14] Schmidt A, Marabita F, Kiani N A, et al. Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3[J]. BMC Biol, 2018, 16(1): 47.
[15] 孙丹丹,马晴晴,徐元宏,等. 肝细胞癌患者调节性T细胞与NK细胞相关性研究[J]. 安徽医科大学学报,2020,55(11):1666-1670.
[16] 刘冬宇,白劼,白红艳. 肝细胞癌组织中Foxp 3+调节性T淋巴细胞表达水平及其与肿瘤免疫相关性研究[J]. 陕西医学杂志,2021,50(8):1019-1022.
[17] 徐加成,李伟,李涛,等. 叉头盒蛋白P3基因调控人结肠癌细胞生物学行为及其机制[J]. 中华实验外科杂志,2022,39(3):438-441.
[18] 白洁,王中良,李晶. 进展期胃癌组织中ESM-1、IGFBP3、FOXP3的表达及对其预后的影响[J]. 实用癌症杂志,2022,37(4):536-539.
[19] Khan KN, Yamamoto K, Fujishita A, Koshiba A, Kuroboshi H, Sakabayashi S, Teramukai S, Nakashima M, Kitawaki J. Association between FOXP3+ regulatory T-cells and occurrence of peritoneal lesions in women with ovarian endometrioma and dermoid cysts. Reprod Biomed Online. 2019 Jun;38(6):857-869.
[20] 张雅丽,侯安丽,王杏茶,等. 84例子宫内膜癌中Foxp3的表达及临床意义[J]. 临床与实验病理学杂志,2015(7): 748-751.
[21] Xi Z, Jing L, Le-Ni K, Zhu L, Ze-Wen D, Hui Y, Ming-Rong X, Guang-Dong L. Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study. Medicine (Baltimore). 2019 Jul;98(30):e16345.
[22] 杨菲,薛婷,陈松,等. TGF-β刺激对小鼠脾脏树突状细胞功能的影响[J]. 中华微生物学和免疫学杂志,2017, 37(3):165-170.
[23] 张亚楠,季旭明,韩晓春,等. TGF-β在肿瘤免疫微环境中的作用及研究进展[J]. 医学研究杂志,2017,46(4):8-10.
[24] Zhang HH,Li R, Li YJ,Yu XX,Sun QN,Li AY, Kong Y.eIF4E-related miR-320a and miR-340-5p inhibit endometrial carcinoma cell metastatic capability by preventing TGF-β1-induced epithelial-mesenchymal transition. Oncol Rep.2020 Feb;43(2):447-460.
[25] Kurnit KC, Draisey A, Kazen RC, Chung C, Phan LH, Harvey JB, Feng J, Xie S, Broaddus RR, Bowser JL. Loss of CD73 shifts transforming growth factor-β1 (TGF-β1) from tumor suppressor to promoter in endometrial cancer. Cancer Lett. 2021 May 1;505:75-86.
[26] Dwivedi SKD, Rao G, Dey A, Buechel M, Zhang Y, Zhang M, Yang D, Mukherjee P, Bhattacharya R. Targeting the TGFβ pathway in uterine carcinosarcoma. Cell Stress. 2020 Aug 25;4(11):252-260.
[27] 刘艺,周伟,郗晓燕.消化道出血患者CD4~+CD25~+Treg细胞及其细胞因子TGF-β1、IL-10与预后的相关性[J].热带医学杂志,2021,21(04):508-511+519.
[28] 吴华仙,田广俊,陈曲波.IL-10^+调节性B细胞在自身免疫性疾病中的研究进展[J].中国免疫学杂志,2016,32(7):1077-1079+1083.
[29] Coosemans AN, Baert T, D'Heygere V, Wouters R, DE Laet L, VAN Hoylandt A, Thirion G, Ceusters J, Laenen A, Vandecaveye V, Vergote I. Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer. Anticancer Res. 2019 Nov;39(11):5953-5962.
[30] 肖庆,刘莉,胡雅君,等. miR-125b-5p靶向STAT3调控免疫因子IL-6/10的表达抑制子宫内膜癌细胞的增殖、迁移和侵袭的机制研究[J]. 免疫学杂志,2019,35(7): 553-560.
[31] 李林,程矗,段瑞岐,等. IL-10、IL-17在子宫内膜癌中的表达及意义[J]. 四川大学学报（医学版）,2014,45(5): 793-796.
[32] 戚益铭,吴霜霜,陈观平,虞宝磊,应栩华,汪一帆.扶肺煎对Lewis肺癌移植瘤生长及肿瘤微环境中Foxp3~+Tregs、Foxp3、IL-10、TGF-β的影响[J].辽宁中医杂志,2022, 49(02): 187-190+227-228.
[33] 于丹军,樊静,胡月,等. 宫颈癌患者外周血中CD4+CD25+Foxp3+调节性T淋巴细胞及血清中IL-10、TGF-β的表达及其临床意义[J]. 标记免疫分析与临床,2016,23(10):1185-1190,1236.
[34] 赵琳蕾,王婷,冯超蕙,等. CD4+CD25+调节性T细胞与子宫内膜癌的相关性及其在免疫逃逸中的作用机制研究[J]. 中国优生优育,2012,18(6):343-348.
[35] 龙佑梅,黄梨,王艳清,等. 晚期子宫内膜癌的免疫微环境研究进展[J]. 医学综述,2019,25(23):4681-4685.
[36] 秦绪颖,刘秀芳,张丽丽,等. PD-1、PD-L1蛋白在子宫内膜癌组织中的表达及其临床意义[J]. 肿瘤预防与治疗,2022,35(2):111-119.